Case Report of Dinutuximab-induced Atypical Hemolytic Uremic Syndrome.

Limited evidence exists describing the relationship between the development of atypical hemolytic uremic syndrome (aHUS) and the administration of dinutuximab. This case report describes a 20-year-old male with neuroblastoma who experienced aHUS post-dinutuximab administration. The patient presented with uncontrolled hypertension and renal dysfunction, ultimately receiving a definitive diagnosis of aHUS through a renal biopsy. The patient required complement-directed therapy with eculizmab and later transitioned to ravulizumab. This case further describes a sequential relationship between dinutuximab administration and aHUS development.